Raptiva has been withdrawn from the market due to the possible risk of developing progressive multifocal leukoencephalopathy (PML). Many psoriasis sufferers are greatly concerned. Some users of this psoriasis drug have been taking it for several years and are just now finding out that they might be at risk.
PML leads to a gradual worsening in the way the nervous system works, which cannot be reversed, and death. People who have taken Raptiva and have severely weakened immune systems are most at risk. Longer, continuous use may further increase the risk. There is a website (www.psoriasis.org) that you might want to go to for more information. If you need additional information, you can contact Ben Locklar at 800-898-2034 or by email at Ben.Locklar@beasleyallen.com.
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.